Diabetes
Do GLP-1 drugs show pancreatitis safety signals?
Open access · cc by · source: Europe PMC
Across 6,751 FAERS ICSRs (plus 39 case-series patients), AP reporting signals appeared for all studied GLP-1 RAs, especially exenatide and liraglutide.
Study at a glance
- Design
- Other — Case series plus FAERS disproportionality pharmacovigilance for GLP-1 RA–associated AP
- N
- N=6751 · 6,751 FAERS ICSRs; case series n=39 AP events
- Population
- FAERS reports and case-series patients with AP while on GLP-1 RAs
- Outcome
- Disproportionality signals for acute pancreatitis across GLP-1 RA agents
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Median age 57; 98.3% of FAERS cases serious. AP signals across agents, with emphasis on exenatide and liraglutide.
Methodology
Reviewed AP case reports and mined FAERS (2005–2023) with ROR/PRR/BCPNN/MGPS for seven GLP-1 RAs including tirzepatide.
Limitations
Spontaneous reporting signals are not incidence rates or proof of causality vs confounding by indication.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
GLP-1RAs can be studied as add-on therapy to insulin in type 1 diabetes.
A systematic/clinical synthesis evaluates glucagon-like peptide-1 receptor agonists added to insulin for type 1 diabetes—glucose and weight outcomes under insulin co-therapy.
Scope note — pancreatitis case series ≠ T1D efficacy trial
Limits the claim's scope: a different population, assay, or outcome.
Different GLP-1RAs have been linked to acute pancreatitis in pharmacovigilance-style case series.
A case-series analysis associates specific GLP-1 receptor agonists with acute pancreatitis reports—useful for safety signal literacy, not incidence rates.
Evidence for the claim as stated.
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
Related papers in this topic
Same topic cluster — not a recommendation engine.